10月29日，南方医院心血管内科修建成团队成功应用国产肾神经标测/选择性消融系统为一例难治性高血压和一例药物不耐受高血压患者施行经肾动脉去肾交感神经术 (renal ...

Medtronic (NYSE:MDT) today announced new, long-term study data further supporting its Symplicity Spyral renal denervation ...

Medtronic and Recor Medical may have some fresh resolutions for the new year after the Centers for Medicare & Medicaid ...

With a focus on innovation, patient-centered care, and collaboration, Pulnovo Medical, a rising star in the realm of ...

Medtronic and Recor Medical each announced separate Medicare reimbursement approvals for their respective renal denervation ...

Medtronic announces new long-term favorable data for its Symplicity Spyral RDN system, which has undergone a SPYRAL HTN-ON ...

Furthermore, as there is no evidence of benefit of renal denervation in poorly compliant patients, drug adherence should be evaluated using validated questionnaires or, preferably, dosage of drug ...

In October 2022, Mike Bowers began experiencing severe headaches and what seemed like vertigo. He also was beginning to have ...

The U.S. Medicare outpatient final rule affirms several new devices for the new technology pass-through program, but one of the more significant findings is that CMS will use separate payment ...

About a year ago, renal denervation procedures won a huge victory after finally being greenlit by FDA. Now two of the frontrunners in the space have received reimbursement.

Patient and physician education is the next challenge to change the treatment paradigm for drug-resistant hypertension, Citi Research analyst Joanne Wuensch said.